TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc. (TBPH) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 6% planned / 94% discretionary
Largest single sale: $4.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner | Sell | 37,799 | $17.00 | $642.6K | 9,174,453 −0.4% of holding | |
| Samaha Eli | 10% Owner | Sell | 25,027 | $17.13 | $428.8K | 9,212,252 −0.3% of holding | |
| Samaha Eli | 10% Owner | Sell | 273,871 | $17.23 | $4.7M | 9,237,279 −2.9% of holding | |
| Farnum Rhonda 3 fills | SVP, COMM & MEDICAL AFFAIRS | Sell | 13,314 | $16.39 | $218.2K | 242,442 −5.2% of holding | |
| Farnum Rhonda 3 fills | SVP, COMM & MEDICAL AFFAIRS | Sell | 31,067 | $13.96 | $433.6K | 255,999 −10.8% of holding | |
| Farnum Rhonda 3 fills | SVP, COMM & MEDICAL AFFAIRS | Sell | 31,067 | $18.75 | $582.5K | 300,995 −9.4% of holding | |
| BROSHY ERAN 2 fills | Director | Sell 10b5-1 | 29,501 | $20.00 | $590.0K | 60,204 −32.9% of holding | |
| BROSHY ERAN 6 fills | Director | Sell | 104,000 | $18.05 | $1.9M | 75,704 −57.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.